Cardiol To Test Oral Cannabidiol Formulation In Acute Myocarditis Patients

The FDA has signed off Cardiol Therapeutics Inc's CRDL Investigational New Drug (IND) application for CardiolRx.
Cardiol will commence a Phase 2, multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and tolerability of CardiolRx in acute myocarditis patients.
Myocarditis is an acute inflammatory condition of the myocardium, characterized by inflammation of the heart muscle.
The study will enroll 100 patients.
The primary endpoints of the trial, which will be evaluated after 12 weeks of double-blind therapy, consist of left ventricular function (ejection fraction and longitudinal strain) and myocardial edema (extra-cellular volume).
CardiolRx is a pharmaceutically produced oral cannabidiol formulation investigated in Phase 2/3 outcomes study (the LANCER trial) to evaluate CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events.
Related content: Benzinga's Full FDA Calendar.
Price Action: CRDL shares are up 9.90% at $3.33 during the premarket session on the last check Tuesday.